Istodax FDA Approval History
FDA Approved: Yes (First approved November 5, 2009)
Brand name: Istodax
Generic name: romidepsin
Dosage form: for Injection
Company: Gloucester Pharmaceuticals
Treatment for: Cutaneous T-cell Lymphoma
Istodax (romidepsin) a histone deacetylase (HDAC) inhibitor indicated the treatment of cutaneous T-cell lymphoma and peripheral T-cell lymphoma.
Development Timeline for Istodax
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.